Academic literature on the topic '709.440 9033'

ABSTRACTTorezolid (TR-700) is the active moiety of the prodrug torezolid phosphate ([TP] TR-701), a second-generation oxazolidinone with 4- to 16-fold greater potency than linezolid against Gram-positive species including methicillin-resistantStaphylococcus aureus(MRSA). A double-blind phase 2 study evaluated three levels (200, 300, or 400 mg) of oral, once-daily TP over 5 to 7 days for complicated skin and skin structure infections (cSSSI). Patients 18 to 75 years old with cSSSI caused by suspected or confirmed Gram-positive pathogens were randomized 1:1:1. Of 188 treated patients, 76.6% had abscesses, 17.6% had extensive cellulitis, and 5.9% had wound infections.S. aureus, the most common pathogen, was isolated in 90.3% of patients (139/154) with a baseline pathogen; 80.6% were MRSA. Cure rates in clinically evaluable patients were 98.2% at 200 mg, 94.4% at 300 mg, and 94.4% at 400 mg. Cure rates were consistent across diagnoses, regardless of lesion size or the presence of systemic signs of infection. Clinical cure rates in patients withS. aureusisolated at baseline were 96.6% overall and 96.8% for MRSA. TP was safe and well tolerated at all dose levels. No patients discontinued treatment due to an adverse event. Three-stage hierarchical population pharmacokinetic modeling yielded a geometric mean clearance of 8.28 liters/h (between-patient variability, 32.3%), a volume of the central compartment of 71.4 liters (24.0%), and a volume of the peripheral compartment of 27.9 liters (35.7%). Results of this study show a high degree of efficacy at all three dose levels without significant differences in the safety profile and support the continued evaluation of TP for the treatment of cSSSI in phase 3 trials.

Clinical nursing care practice is a crucial role in ensuring quality care for patients and contiuously quality improving for healthcare services. Objectives: this study aims to describe the status of clinical nursing care practice and analyse some associated factors among nurses in healthcare facilities in Bac Giang province in 2023. Method: A cross-sectional study was employed among nurses at the clinical departments in 10 healthcare facilities in Bac Giang provinces (including 01 provincial general hospital and 09 districal healthcare centres). A total of 700 nurses were selected in this study. Results: The main findings showed that the clinical nursing care practice reached at 70.9% in general. In which, the proportion of nurses had achieved the standard 6 “Performing clinical care techniques according to the procedures" at the highest rate (90.3%) and the standard 11 "Communicating effectively with patients and their families" at the lowest rate (73.7%). The average score for clinical care practice among nurses ranged from 4.0 to 4.2. The results indicated that participating in training, job satisfaction and satisfaction with the equipment had a significant association with the clincal nursing care practice (p<0.05). Conclusions: Strengthening training and regularly ensuring a working environment with adequate equipment and ensuring job satisfaction is a necessary factor to contribute for improving the clincal nursing care practice at public healthcare facilities in Bac Giang province. Keywords: Nurses, competencies, clincal nursing care practice, health workforce, Vietnam.

Genetic variation is needed for developing new superior varieties in plant breeding. Genetic variation of chili plants could be increased by inducing mutation with gamma rays irradiation. The aim of this study was to determine radiosensitivity of two local varieties of chili pepper by calculating the lethal dose values at LD20 and LD50. Chili pepper (Capsicum frutescens L.) seeds of local varieties origin from Tulungagung and Ponorogo were irradiated with cobalt-60 gamma rays at doses of: 0; 100; 200; 300; 400; 500; 600; 700; 800; 900; 1000 Gray (Gy); each as many as 50 seeds per dose of radiation. The irradiated chili seeds were grown in small polybags containing 1:1 mixture of soil and compost. Germination parameters of chili seeds was observed 30 days after planting (DAT) to determine lethal dose of 20 (LD20) and lethal dose of 50 (LD50). The results showed that increasing doses of gamma rays caused greater damage to chili seeds therefore the seeds were not able to germinate. Local Tulungagung Variety had LD20 and LD50 of 147.62 Gy and 409.52 Gy; and the Local Ponorogo variety had LD20 and LD50 of 90.3 Gray and 453.7 Gray. Local Tulungagung Variety was more sensitive to gamma rays than Local Ponorogo Variety. LD20 and LD50 can be used to get a lot of genetic variation and obtaining the positive mutants. Keywords: Irradiation, Genetic variation, Lethal dose, Mutation

Abstract The Molten Salt Reactor (MSR) is a type of reactor in which coolant and fuel are blended with liquid salts. Liquid fuel enhances heat transfer and temperature control, establishing the MSR as one of the Generation IV reactor types. This study aims to analyze the impact of temperature variations on MSR reactor criticality and evaluate the effect of different nuclear data libraries, namely JENDL 3.2, JENDL 3.3, and JENDL 4.0, in neutron analysis. The observed temperature variations are 600 K, 700 K, 833 K, 903 K, and 1000 K. The analysis spans low to operational temperatures to comprehend reactor performance under differing thermal conditions. The study is conducted on a 300 MWTh MSR design, utilizing SRAC2006 with PIJ and CITATION modules for calculations. The results reveal the impact of temperature variations and nuclear data library disparities on reactor criticality. The outcomes demonstrate that higher temperatures correspond to lower values of the effective multiplication factor. At lower temperatures, neutrons experience greater moderation compared to higher temperatures. As a result, a higher number of thermal neutrons influences an increased probability of fission reactions within the reactor. Different nuclear data libraries also yield varied criticality values due to differing cross-sectional areas and quantities of data within each JENDL library. JENDL 4.0 generates the highest criticality value, attributed to elevated cross-sectional regions of each respective nuclear data entry and a greater quantity of nuclear data entries than JENDL 3.2 and JENDL 3.3.

A total of 700 carotid endarterectomies have been performed over a 24-year period at the authors' institute; of these patients 632 (90.3%) had unilateral and 68 (9.7%) had bilateral disease. Some 71 patients who declined operation were followed-up to obtain the natural history of carotid disease. The operative results were compared against this untreated group of patients. Surgical endarterectomy was recommended for a recovered stroke in 190 patients (27.1%), progressive ischaemia in 20 (2.9%) and transient ischaemic attacks in 410 (58.6%). A group of 100 patients with non-specific symptomatology, who were considered ‘symptom-free’, were also operated on; none of these died or developed permanent postoperative neurological defects. The mean age of patients was 56 (range 28-86) years. The overall operative mortality rate was 0.8%. Perioperative neurological deficits occurred in 0.5% and temporary cranial nerve injury in 1.8%. The follow-up covered a period of 10 years, but was in several instances extended to 14 years. The incidence of late neurological events in the patients having an endarterectomy was 3%. In the non-operated group, 12% of normotenslve and 18% of hypertensive patients developed symptoms. The 10-year postoperative survival rate was 80% in the symptom-free group of patients. 70% in those with transient ischaemic attacks and 60% in those who had a previous stroke.

9036 Background: Ipilimumab is a fully human monoclonal antibody against cytotoxic T-lymphocyte antigen-4. In total, ∼50% of metastatic melanoma pts treated with 10 mg/kg ipilimumab are alive at 1 year (Wolchok et al. CRI-CVC annual meeting 2008. Oral presentation), and identifying prognostic factors may help select pts most likely to benefit from treatment. Factors predictive of poorer prognosis in melanoma include advanced stage of disease (ie, M1c), age 60+, gender (male), elevated baseline lactate dehydrogenase (LDH) levels, and lack of a prior response to therapy. In this pooled analysis, potential prognostic factors in pts with advanced melanoma treated with ipilimumab 10 mg/kg in 2 phase II studies (CA184–008, N=155 and -022, N=72) were explored. Methods: Ipilimumab 10 mg/kg was given every 3 weeks (Q3W) × 4 (induction); eligible pts could continue to receive ipilimumab Q12W starting at week (Wk) 24 (maintenance). Response was based on modified World Health Organization criteria. Each variable was analyzed separately. Results: Disease control rate (complete/partial response [CR/PR] and stable disease) seems not to be associated with age (<65 yrs: 25.2%; ≥65 yrs: 32.9%), gender (male: 22.6%; female: 34.0%), M stage (M0: 33.3%; M1a: 41.0%; M1b: 26.4%; M1c: 23.6%), response to prior systemic therapy (yes: 32.5%; no: 26.7%), prior immunotherapy (yes: 21.6%; no: 35.3%), LDH >upper normal limit (UNL) (yes: 25.9%; no: 29.7%), or LDH >2×UNL (yes: 15.9%; no: 30.6%). Best overall response rate (CR or PR) was not associated with age (<65 yrs: 7.3%; ≥65 yrs: 7.9%), gender (male: 4.0%; female: 11.7%), M stage (M0: 8.3%; M1a: 15.4%; M1b: 5.7%; M1c: 5.7%), response to prior systemic therapy (yes: 12.5%; no: 6.4%), prior immunotherapy (yes: 3.2%; no: 12.7%), LDH >UNL (yes: 8.6%; no: 6.3%), or LDH >2×UNL (yes: 4.5%; no: 8.2%). Overall survival was not associated with age (median OS: <65 yrs: 11.6 mo; ≥65 yrs: 7.59 mo), M stage (median OS: M0: 21.9 mo; M1a: 15.7 mo; M1b: 15.4 mo; M1c: 6.6 mo), or response to prior systemic therapy (median OS: yes: 11.6 mo; no: 10.7 mo). Conclusions: Ipilimumab demonstrates clinical activity independent of negative prognostic factors, and may even benefit those pts with the worst prognosis. [Table: see text]

ABSTRACT Occult hepatitis C virus (HCV) infection of patients with abnormal liver function tests of unknown origin who are anti-HCV and serum HCV RNA negative but who have HCV RNA in the liver has been described. As HCV replicates in the liver cells of these patients, it could be that the amount of circulating viral particles is under the detection limit of the most sensitive techniques. To prove this hypothesis, serum samples from 106 patients with occult HCV infection were analyzed. Two milliliters of serum was ultracentrifuged over a 10% sucrose cushion for 17 h at 100,000 × g av, where av means average, and HCV RNA detection was performed by strand-specific real-time PCR. Out of the 106 patients, 62 (58.5%) had detectable serum HCV RNA levels after ultracentrifugation, with a median load of 70.5 copies/ml (range, 18 to 192). Iodixanol density gradient studies revealed that HCV RNA was positive at densities of 1.03 to 1.04 and from 1.08 to 1.19 g/ml, which were very similar to those found in the sera of patients with classical chronic HCV infection. Antigenomic HCV RNA was found in the livers of 56 of 62 (90.3%) patients with detectable serum HCV RNA levels after ultracentrifugation, compared to 27 of 44 (61.4%) negative patients (P < 0.001). No differences in the median loads of antigenomic HCV RNA between patients with an those without serum HCV RNA (4.5 × 104 [range, 7.9 × 102 to 1.0 × 106] versus 2.3 × 104 [range, 4.0 × 102 to 2.2 × 105]) were found. Alanine aminotransferase and gamma-glutamyl transpeptidase levels, liver necroinflammatory activity, and fibrosis did not differ between both groups. In conclusion, HCV RNA can be detected in the sera of patients with occult HCV infection after circulating viral particles are concentrated by ultracentrifugation.

<p><em>UMKM Keripik Tahfidz Qur’an Yayasan Al Amaliah merupakan mitra Desa Binaan Universitas Al Azhar Indonesia (UAI). UMKM ini dikategorikan sebagai UMKM masyarakat yang belum produktif secara ekonomis, tetapi berhasrat kuat menjadi wirausahawan. UMKM ini beranggotakan 9 orang dari ibu-ibu pengajian. Keripik yang diproduksi oleh mitra UMKM ini, diberi nama dagang berturut-turut keripik CIKIKONG (Cikidang singkong), CIKILED (Cikidang boled, ubi) dan CIKISANG pisang (Cikidang pisang). Bahan dasar keripik Cikidang memiliki citra rasa yang khas sehingga menjadi peluang besar bagi mitra UMKM ini untuk memperbesar unit usaha keripik agar bisa menembus pasaran lokal sebagai oleh-oleh khas Sukabumi yang berasal dari Desa Cikidang Sukabumi. Melalui Dana Desa Binaan UAI 2020 telah dilakukan pelaksanaan abdimas dengan pemberian seperangkat unit mesin produksi teknologi tepat guna (TTG) hasil rekayasa Perguruan Tinggi tim pelaksana abdimas. Kegiatan difokuskan pada edukasi (pelatihan) dan sosialisasi terutama pada penanganan mesin produksi, manajemen produksi, perawatan-perbaikan mesin produksi, dan keselamatan kerja.H</em><em>asil kegiatan diperoleh berturut-turut perajangan bahan singkong dan ubi menggunakan mesin rajang otomatis diputar pada kecepatan 800-900 rotate per minute (rpm), perajangan bahan pisang dengan mesin manual pada kecepatan 200-300 rpm. Penggunaan ketel penggorengan deep frying 6 liter minyak, untuk mempertahankan rasa, warna dan aroma, maka bahan singkong, ubi dan pisang harus digoreng pada suhu berturut-turut 120</em><em>o</em><em>C, 120</em><em>o</em><em>C, dan 100</em><em>o</em><em>C, dengan lama waktu berturut-turut 5 menit, 4 menit, dan 7 menit. Hasil edukasi penggunaan mesin spinner (peniris) akan optimal apabila hasil gorengan keripik singkong, ubi dan pisang ditempatkan pada kecepatan putaran spiner berturut-turut 600 rpm, 400 rpm, dan 700 rpm dengan lama waktu berturut-turut 3 menit, 3 menit, dan 4 menit. Penggunaan mesin sealer plastik kemasan akan optimal pada suhu 270</em><em>o</em><em>C untuk semua jenis plastik pouch. Ditunjukan indikator keberhasilan penerapan TTG pada UMKM, terjadi kenaikan kuantitas produk keripik singkong, ubi dan pisang berturut-turut sebesar 52.8 %, 38.2 % dan 33.3 %, diperlihatkan juga terjadi kenaikan kualitas produk berturut-turut sebesar 77.3 %, 90,3 % dan 86.7 %.</em></p><p><strong>Kata kunci<em>: </em></strong><em>Teknologi Tepat Guna Produk Keripik</em></p>

This work deals with the wafer-level integration of advanced group III-V devices and integrated circuits on silicon substrate for RF-sensor integration, such as radar functions a very high frequencies beyond 300 GHz [1]. The aim is to achieve both performance improvements on device level, co-integration with digital functions, and advanced integration to achieve a greener usage of material critical to the environment. Submillimeter-Wave frequency bands beyond 300 GHz allow for broadband transmit and receive windows, serviceable to both communications and radar-based applications—increasing data rates and imaging resolutions, respectively. On the other hand, CMOS co-integration is called for by the data acquisition- and other mixed-mode- and fast digital functions. As examples of the integration schemes Terahertz Monolithic Integrated Circuit amplifiers (TMICs) are implemented in an advanced transferred-substrate InGaAs-channel HEMT technology with 20-nm gate length on silicon. The inverted III-V HEMT heterostructure is grown by molecular beam epitaxy (MBE) on 100-mm semi-isolating GaAs wafers and transferred to silicon substrates by using a SiO2-based wafer bond process with subsequent wafer thinning and removal of the GaAs substrate. Thus, only a 100-nm-thick III-V heterostructure layer is remaining on the Si substrate. This advanced transferred-substrate technology also offers the implementation of HEMT devices with backside gate [2,3] to achieve better sub-threshold slope, or field plates to increase both channel confinement and higher breakdown voltages. The 20-nm InGaAs-OI HEMT technology features typical values for the OFF-state breakdown voltage of 5 V and and maximum drain-current density of 1200 mA/mm, respectively. A maximum transconductance of 2400 mS/mm is achieved. The expected cutoff frequency values fT and fmax are above 500 GHz and 1 THz, respectively [4]. A fully passivated back-end-of-line (BEOL) process is used, including three metal layers (MET1–MET3). A NiCr 50 Ohm sq thin-film-resistor layer, as well as an SiN layer for the implementation of MIM capacitors between MET2 andMET3. S-parameter characteristics of a six-stage and nine-stage TMIC amplifiers in the frequency band from 620 to 730 GHz are given as examples. During the on-wafer characterization, the HEMT devices in cascode configuration have been biased at VD= 2 V (1 V drain–source voltage per device) and a current of 350 mA/mm. The measured small-signal gain of the six-stage cascode TMIC amplifier is in the range of 22–25 dB over the frequency range from 670 to above 700 GHz. This corresponds to 4 dB of gain per cascode stage around the 670-GHz frequency range. A nine-stage TMIC amplifier, on the other hand, achieves at least 30 dB of measured gain from 660 to about 700 GHz. This again corresponds to a gain per stage below 4 dB. Such results prove both the advancements in integration as well as state-of-the-art circuit performance co-integrated on silicon. References: [1] B. Gashi et al., "Broadband 400 GHz On-Chip Antenna With a Metastructured Ground Plane and Dielectric Resonator," in IEEE Transactions on Antennas and Propagation, vol. 70, no. 10, pp. 9025-9038, Oct. 2022, doi: 10.1109/TAP.2022.3177527. [2] A. Tessmann et al., "20-nm In0.8Ga0.2As MOSHEMT MMIC Technology on Silicon," in IEEE Journal of Solid-State Circuits, vol. 54, no. 9, pp. 2411-2418, Sept. 2019, doi: 10.1109/JSSC.2019.2915161. [3] A. Leuther et al., "InGaAs HEMT MMIC Technology on Silicon Substrate with Backside Field-Plate," 2020 50th European Microwave Conference (EuMC), 2021, pp. 187-190, doi: 10.23919/EuMC48046.2021.9337957. [4] L. John, et al., "High-Gain 670-GHz Amplifier Circuits in InGaAs-on-Insulator HEMT Technology," in IEEE Microwave and Wireless Components Letters, vol. 32, no. 6, pp. 728-731, June 2022, doi: 10.1109/LMWC.2022.3160093.

Abstract Background: Medical financial hardship, encompassing material, behavioral, and psychologic domains, is becoming an increasingly common consequence of illness in cancer patients. Identifying at-risk patients is the first step to develop proactive approaches to mitigate this problem. To try and address this need, Mayo Clinic Breast Disease Registry (MCBDR) is prospectively collecting data about financial concerns in addition to the usual sociodemographic and clinical information. Methods: We used data from Mayo Clinic Breast Disease Registry, a prospective cohort of consenting patients seen at Mayo Clinic Rochester within one year of initial breast cancer diagnosis. Participants completed baseline and annual follow-up surveys rating their financial concerns on a linear analogue scale from 0 (“none”) to 10 (“constant concerns”). We compared patient-reported financial concern at baseline to that on each patient’s most recent survey, with worsening concerns defined as a 1+-point increase. Logistic regression evaluated for predictors of worsening financial concerns. Results: 1,957 participants responded to financial concern questions on a baseline and at least one follow-up survey between 2015 and 2020. Mean age was 58.5 years (SD 12.5), and mean time between diagnosis and the most recent follow-up was 25.6 months (SD 16.2). 357 (18.2%) reported worsening financial concerns. Only lower baseline financial status was associated with a greater likelihood of worsening financial concerns (see Table). Conclusions: More than one in seven breast cancer survivors develop worsening financial concerns within 5-years of diagnosis, and those with less financial security at baseline appear to be most vulnerable. Funding: Breast Cancer Research Foundation (CLL) and NR015259 (KJR). Patient and tumor characteristics, compared by whether financial status worsened over time Full Cohort (n=1957) Worsening, ≥ 1-point change (n=357) Stable/Improved (n=1600) p value Full Cohort (n=1957) Worsening, ≥ 1-point change (n=357) Stable/Improved (n=1600) p value Age at diagnosis II or III 502 (25.7%) 98 (27.5%) 404 (25.3%) 0.239 ≤ 50 546 (27.9%) 105 (29.4%) 441 (27.6%) IV 67 (3.4%) 17 (4.8%) 50 (3.1%) 0.086 51-64 757 (38.7%) 136 (38.1%) 621 (38.8%) 0.562 Unknown 351 (17.9%) 65 (18.2%) 286 (17.9%) 0.536 ≥65 654 (33.4%) 116 (32.5%) 538 (33.6%) 0.506 ER and/or PR positive Race No/Unknown 482 (24.6%) 92 (25.8%) 390 (24.4%) White 1863 (95.2%) 337 (94.4%) 1526 (95.4%) Yes 1475 (75.4%) 265 (74.2%) 1210 (75.6%) 0.580 Non-white 24 (1.2%) 5 (1.4%) 19 (1.2%) 0.729 Her2 positive Other/Unknown/Choose not to respond 70 (3.6%) 15 (4.2%) 55 (3.4%) 0.478 No/Unknown 1746 (89.2%) 314 (88.0%) 1432 (89.5%) Educational status Yes 176 (9.0%) 37 (10.4%) 139 (8.7%) 0.321 Less than bachelor’s degree 880 (45.0%) 168 (47.1%) 712 (44.5%) Borderline 35 (1.8%) 6 (1.7%) 29 (1.8%) 0.898 Bachelor's degree or higher 1065 (54.4%) 187 (52.4%) 878 (54.9%) 0.384 Radiation Unknown 12 (0.6%) 2 (0.6%) 10 (0.6%) 0.832 No/Unknown 781 (39.9%) 140 (39.2%) 641 (40.1%) Financial status near time of diagnosis Yes 1176 (60.1%) 217 (60.8%) 959 (59.9%) 0.768 Pay bills, money for special things 1412 (72.2%) 244 (68.3%) 1168 (73.0%) Chemotherapy/targeted therapy Pay bills, no money for special things 367 (18.8%) 80 (22.4%) 287 (17.9%) 0.046 No/Unknown 1264 (64.6%) 221 (61.9%) 1043 (65.2%) Pay bills by making cuts 102 (5.2%) 19 (5.3%) 83 (5.2%) 0.729 Yes 693 (35.4%) 136 (38.1%) 557 (34.8%) 0.241 Unable to pay bills 56 (2.9%) 10 (2.8%) 46 (2.9%) 0.911 Hormone/endocrine therapy Unknown 20 (1.0%) 4 (1.1%) 16 (1.0%) 0.750 No/Unknown 710 (36.3%) 141 (39.5%) 569 (35.6%) Employment status at time of diagnosis Yes 1247 (63.7%) 216 (60.5%) 1031 (64.4%) 0.163 Employed full-time 462 (23.6%) 83 (23.2%) 379 (23.7%) Surgery type Employed part-time/unemployed/retired 525 (26.8%) 92 (25.8%) 433 (27.1%) 0.856 Lumpectomy 846 (43.2%) 145 (40.6%) 701 (43.8%) Not available 970 (49.6%) 182 (51.0%) 788 (49.3%) 0.716 Mastectomy 903 (46.1%) 165 (46.2%) 738 (46.1%) 0.535 Stage at time of diagnosis None/Unknown 208 (10.6%) 47 (13.2%) 161 (10.1%) 0.069 0 or I 1037 (53.0%) 177 (49.6%) 860 (53.8%) Citation Format: Michael H. Storandt, Urshila Durani, Daniela Stan, Nicole Larson, Charles Loprinzi, Fergus Couch, Janet E. Olson, Nandita Khera, Kathryn J. Ruddy. Financial hardship in breast cancer survivors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1012.